1. Home
  2. HOUR vs EQ Comparison

HOUR vs EQ Comparison

Compare HOUR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

N/A

Current Price

$1.98

Market Cap

66.8M

ML Signal

N/A

EQ

Equillium Inc.

HOLD

Current Price

$2.01

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOUR
EQ
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.8M
64.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
HOUR
EQ
Price
$1.98
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
6.7K
642.1K
Earning Date
05-11-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
150.00
N/A
EPS
0.05
N/A
Revenue
$142,440,236.00
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$36.40
N/A
Revenue Growth
3.03
N/A
52 Week Low
$1.10
$0.29
52 Week High
$6.84
$2.70

Technical Indicators

Market Signals
Indicator
HOUR
EQ
Relative Strength Index (RSI) 60.78 53.77
Support Level $1.75 $1.38
Resistance Level $2.08 $2.30
Average True Range (ATR) 0.06 0.19
MACD 0.00 -0.03
Stochastic Oscillator 88.98 62.86

Price Performance

Historical Comparison
HOUR
EQ

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: